OmniComm Announces the Release of OmniConnect™ for Seamless Exchange and Analysis of Study Data 

Fort Lauderdale, FL, February 25, 2010 - OmniComm Systems, Inc. (OTC: OMCM.OB), a global provider of eClinical solutions, announced that it released a new Application Programming Interface (API), OmniConnect™. OmniConnect is a REST, web services, API based on an extended CDISC ODM dataset. The use of REST web services in the API is the first of its kind in the industry. "This new API follows OmniComm’s continued focus on interoperability and providing value based solutions," said Randy Smith, CTO of OmniComm Systems. "OmniConnect brings together complex clinical trial management functionality with our TrialMaster™ EDC solution in a single, integrated database. By receiving a consistent stream of data, TrialMaster enables sponsors and sites to take advantage of real-time integration of disparate information and data sources."

"This very flexible solution has many applications and has already been deployed with customers in on-going clinical studies, both in the US and in Europe. One of our partners, PharmaPros, has utilized OmniConnect to support real-time reporting requirements for three studies, using their trial management application, Dataflow Manager," said Stephen Johnson, COO of OmniComm Systems.

"The OmniConnect REST interface provides us with first-in-class capabilities to retrieve data and its status in real-time. This has enabled PharmaPros to deliver an in-stream, holistic view of trial status through Dataflow Manager. This is an exciting advancement in eClinical technology integration. We look forward to leveraging the unique capabilities of OmniConnect in our continued mission to optimize trial management by leveraging technology innovation," said Nick Neri, VP of Technology at PharmaPros.

A European technology partner is currently deploying OmniConnect to extract clinical trial data from TrialMaster to their IVR/IWR system and to manage effectively their Sponsor’s trial in a cost-effective way. OmniComm’s Johnson added, "Other uses include tracking and report enrollment, safety data, supply management such as dispensation and reconciliation of study drugs, exports to a CTMS; imports of data from central labs, ECG, IVRS and from our soon to be released Phase I data collection and management system, TrialOne™."

About PharmaPros Corporation
PharmaPros Corporation is a technical consulting and solutions provider specializing in data and technology for clinical trials. The company’s innovative approach and deep industry expertise, has resulted in the commercialization of a revolutionary solution that is redefining clinical trials management. The company’s primary solution – Dataflow Manager™ - provides the ability to manage clinical trials using the most accurate and up-to-date information available, enabling trial sponsors and managers to make more rapid, and better-informed decisions during a trial. Through its proprietary processes and tools, PharmaPros provides services to support

About OmniComm
OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's client intuitive pricing model allows companies that range from small, to mid-size to large-scale institutions to efficiently capitalize on their clinical research investments. OmniComm Systems, Inc has U.S. headquarters in Fort Lauderdale, FL and European headquarters in Bonn, Germany, with satellite offices in New Jersey and the United Kingdom, as well as sales offices throughout the U.S. and Europe.

Safe Harbor Disclaimer
Safe Harbor Disclaimer Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

CONTACT: Stephen Johnson at: + 1 954-377-1726

Back